3 research outputs found
Safety & efficacy of lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies – independent review committee data update
Treatment options are limited for patients with
advanced melanoma who have progressed on checkpoint
inhibitors and targeted therapies such as BRAF/MEK inhibitors
(if BRAF-V600E mutated). Adoptive cell therapy utilizing
tumor-infiltrating lymphocytes (TIL) has shown antitumor efficacy with durable responses in heavily pretreated melanoma
patients. Safety and efficacy of lifileucel, a centrally manufactured cryopreserved autologous TIL therapy assessed by both
investigator and an independent review committee (IRC), are
presented
Safety & efficacy of lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies – independent review committee data update
Treatment options are limited for patients with
advanced melanoma who have progressed on checkpoint
inhibitors and targeted therapies such as BRAF/MEK inhibitors
(if BRAF-V600E mutated). Adoptive cell therapy utilizing
tumor-infiltrating lymphocytes (TIL) has shown antitumor efficacy with durable responses in heavily pretreated melanoma
patients. Safety and efficacy of lifileucel, a centrally manufactured cryopreserved autologous TIL therapy assessed by both
investigator and an independent review committee (IRC), are
presented